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Abstract: The rapid outbreak of bird flu challenges the 
outcome of effective vaccine for the upcoming years. The 
recent research established different norms to eliminate flu 
pandemics. This can be made possible with skilled 
experimental analyses and by tracking the recent virulent 
strain and can be broadly applicable with effective testing of 
vaccine efficacy. Every year World Health Organization 
(WHO) reveals the administration of drug and vaccine to 
counter arrest the spread of flu among the population. As there 
are recurrent failures in priming the population, the complete 
eradication of the flu pandemic is still appears to be an 
unresolved problem. To overcome the current scenario, high 
level efforts with theoretical and practical research is required 
and it can enhance the scope in this field. The recent 
advancements also allow the researchers to endeavor effective 
vaccine to meet the emerging flu types. Only the standardized 
vaccination among the population at the time of flu pandemics 
will revolutionalize the current propositions against influenza 
virus. This paper shows the deficiencies of vaccine fitness 
research as there are reported failures and less efficacy of 
vaccine even after priming the population from referred 
evidences and studies. It also shows simple experimental 
approach in detecting the effective vaccine among the vaccines 
announced by WHO. 
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I. INTRODUCTION  
The influenza A virus subtype H1N1 was widespread in the 
year 2009 and was observed first among Mexicans and 
Americans [1].The emergence of H1N1 pandemics presented a 
serious and highly complex public health challenge. During the 
rapid outbreak of pandemics, the potentially imminent 
availability of effective vaccine is found to be the best way of 
protecting people. However the efficacy of the vaccine and the 
protective effects of the vaccine are considered as the 
fundamental strategy on protecting the population from severe 
disease or death. The viral RNA mutates and develops 
resistance, which requires very careful consideration. 
Regardless, well monitored genomic study is strictly needed as 
the virus has the capacity to reassort between several species 
[2]. Through all these distinct features, virus is evolved in to 
human pathogen that is capable of causing a 
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pandemic dimension. The Oseltamivir resistance of this 
particular virus [3] turned to be the more harmful, so that 
the virus would then be capable of easily transmissible 
among people resulting in illnesses related to H1N1 virus 
[4,5,6, and 7]. This work reminds the necessity of vaccine 
efficacy and also inadequate supply of vaccine in many 
scenarios. 
 
The inequity in vaccine supply should be intensely 
monitored to ensure availability of the stockpile at the 
correct time. Such issues are threats to public and should be 
clarified at the earlier in order to protect the population from 
the flu pandemics for social welfare. In addition, one 
concerns about the effectiveness of the vaccine. In such 
situations extensive clinical trials are needed and should be 
supported by large safety databases to ensure the safety in 
priming the population. The ideology is that testing the 
efficacy of vaccine with sequence based method, which 
might be real or perceived and possibly reports vaccine 
efficacy. 
 
II.       RESEARCH BACKGROUND  
H1N1 virus found to be capable of causing sustained and 
widespread human to human infection [8] and the survey report 
says H1N1 is predominant in 5 of 24 years [9]. As with other 
influenza vaccines, the development of effective H1N1 
vaccines is notable in 41 years as this strain found to cause 
severe deaths in both children and adults [10]. One of the 
studies shows the development of Transverse Myelitis in 
association with H1N1 vaccination which demonstrates the less 
efficacy of vaccine [11]. Likewise wide variability in the 
serological assays was observed while testing the efficacy of 
H1N1 vaccine. Similarly other vaccination study shows the 
outbreak of Guillian Barre Syndrome with respect to 
immunization [12]. As outlined in 2006 vaccination report in 
Israel campaign, it is clear that the death occurs 1 per 1000 in a 
week after immunization [13]. More over, it is been proved that 
H1N1 adjuvant vaccines led to more local symptoms [14, 15, 
16, and 17]. In recent past, many studies show failures in safety 
and efficacy of H1N1 vaccine mainly among students and 
health care workers [18, 19, and 20]. As a result difficult 
decisions will probably need to be taken to address this threat. 
In fact, the vaccines should be designed with the purpose of 
stimulating immune response and should possess small 
antigenic distance related to the concurrent virulent strains to 
elicit the immune response [8].
 
 
However, the vaccine also can be designed based on 
sequence similarity between the vaccine strain and the 
concurrent viral strain. As Subunit vaccines for the seasonal 
influenza is very safe and well tolerated, the matching of 
neuraminidase protein sequence with that of vaccine strain is 
been examined for testing the efficacy of vaccine. 
 
III.      METHODOLOGY  
The viral strain used in this study is 
(A/India/NIV1028798/2010(H1N1) and the sequence 
information is obtained from NCBI - Influenza Virus 
Resource. 
(www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html). 
Sequence alignment technique is used to find the protein 
match between the given sequences, perhaps extending 
them to meet specific constraints. It is an essential tool 
for many biological researches and is implemented here 
to evaluate the vaccine efficacy. 
 
Table 1 gives the information about the Viral 
strain, Vaccine Virus and the length of the sequence. It 
also gives the exact matching score between the 
Vaccine and Viral sequence. 
 
The entire vaccine sequences recommended for 
vaccination were retrieved from the WHO website 
(http://www.who.int/influenza/vaccines/virus/recomm
endations/2012south/en/) and the fasta sequences of 
the respective vaccine virus was downloaded from 
NCBI for further analysis. The retrieved fasta 
sequences of all the vaccine virus was subjected to 
alignment with the Influenza A virus sequence 
(A/India/NIV1028798/2010(H1N1). The Genbank ID 
of the Indian virulent virus selected for this evaluation 
is AEM63448.1 which was collected from the 
Influenza virus resource (NCBI). The publicly 
available tool of European Molecular Biological 
Laboratory (EMBL-EBI) is utilized to align the 
sequences using CLUSTAL W. 
 
Table 1: Pairwise sequence Alignment Scores 
between the Indian Human Viral strain protein 
Neuraminidase and the Vaccine viruses. 
 
S.No Sequence A Sequence B (Vaccine Length Score
  viruses) A B (in %)
      
1. Influenza A >gi|227809834|gb|ACP41 566 489 98.0
 virus 107.1| neuraminidase    
 (A/India/NI [Influenza A virus    
 V1028800/ (A/California/04/2009(H1    
 2010 H1N1) N1))]    
      
2. Influenza A >gi|321272925|gb|ADW80 566 469 42.0
 virus 519.1| neuraminidase    
 (A/India/NI [Influenza A virus    
 V1028800/ (A/Perth/16/2009(H3N2))]    
 2010 H1N1)     
      
3. Influenza A >gi|307101756|gb|ADN32 566 466 28.0
 virus 819.1| neuraminidase    
 (A/India/NI [Influenza B virus    
 V1028800/ (B/Brisbane/60/2008)]    
 2010 H1N1)     
      
 
 
IV.      RESULTS AND DISCUSSION  
As compared with other influenza virus, H1N1 shows 
antigenic heterogenicity and can further evolve in to the 
most virulent strain with the progress of time. As a result, 
development of vaccine that is capable of inducing cross 
protective immunity against the current circulating and 
future emerging strains is vitally important. For this 
reason, the use of sequence alignment technique helps 
to identify the best matching protein sequence. The 
preposition of best matching score helps to predict the 
high affinity vaccine. The derived vaccine strain with 
high potentiality can be used with effective clinical 
trials. It is anticipated that if H1N1 evolves in to a 
pandemic strain in future, the current H1N1 vaccine 
strain will not be a perfect match. In this situation the 
application of rapid and simple techniques is needed to 
evaluate an effective vaccine. The strength of this 
study is to show the simple protocol in testing the 
analytical effectiveness of vaccine which could be a 
preliminary estimation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2: Pie Chart Representation of effective vaccine 
based on Sequence Similarity Alignment between vaccine 
and viral strain. 
 
There is no certainty about the rate of success when the 
H1N1 viruses continue to drift. To overcome such 
difficulties, the tracking of previous records of pandemics 
should be maintained and also simple protocols like 
sequence alignment can be done to test the efficacy of 
vaccine against future H1N1 virulent strains. This might 
results in increased cross reactivity as the antigenic distance 
decreases and can able to provide protection against future 
H1N1 viruses. The efficacy of vaccine among the human is 
quantitatively presented (Fig 2) to show the percentage of 
similarity alignment. 
 
 
V.       CONCLUSION  
In this paper, we present a non-rigid approach to jointly 
solve the tasks of effective vaccine determination using 
computational methods for which one may not find 
complicate in applying this strategy at the time of outbreaks. 
The experimental result highlights the possibility of vaccine 
efficacy determination and preferential usage out of all the 
vaccines announced by WHO this year on several pose 
estimation and probabilistic scenarios. 
 
 
 
As presented above, the evaluation of effectiveness of 
vaccine through this approach will reduce the failure rate of 
vaccines. This test is applicable to all variants of Influenza 
Virus and it involves rapid and simple procedures as there is no 
need of expensive equipments. It is appropriate to perform this 
test before the outbreak of pandemics so as to bring down the 
spread of flu at the time of pandemics. Although three 
vaccine strains have been tested in this study, it is shown 
that the strain A/California/01/2009 (H1N1) is more 
effective when compared with the other two strains. Such 
potential vaccination among the population inherently 
increases the immune responses than priming the population 
with A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008. The 
vaccine derived with high efficacy is very safe for seasonal 
influenza. Sequence alignment of capsid proteins either 
hemagglutinin or neuraminidase with that of vaccine strains 
increase the level of uncertainty surrounding the risk of rare 
unanticipated adverse effects. 
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